PTC Therapeutics, Inc. Operating Income
PTC Therapeutics, Inc. (PTCT) reported Operating Income of $148.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-07-30
- PTC Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was $148.98M.
- PTC Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was $44.96M, a 95.37% decline year-over-year.
- PTC Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$71.35M.
- PTC Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was $3.02M.
- PTC Therapeutics, Inc. operating income (loss) for fiscal 2025 was $866.93M.
- PTC Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$302.57M.
- PTC Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$439.50M.
- PTC Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$447.41M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $148.98M 10-Q · filed 2026-07-30 | $193.94M 10-Q · filed 2026-07-30 | $122.59M derived: sum of 3 quarters · filed 2026-07-30 | $125.60M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $44.96M 10-Q · filed 2026-05-07 | -$26.39M derived: sum of 2 quarters · filed 2026-05-07 | -$23.37M derived: sum of 3 quarters · filed 2026-05-07 | -$58.33M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | -$71.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$68.33M derived: sum of 2 quarters · filed 2026-02-19 | -$103.29M derived: sum of 3 quarters · filed 2026-07-30 | $866.93M 10-K · filed 2026-02-19 | ||||
| 2025-09-30 | $3.02M 10-Q · filed 2025-11-04 | -$31.94M derived: sum of 2 quarters · filed 2026-07-30 | $938.28M 10-Q · filed 2025-11-04 | $775.89M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | -$34.96M 10-Q · filed 2026-07-30 | $935.27M 10-Q · filed 2026-07-30 | $772.88M derived: sum of 3 quarters · filed 2026-07-30 | $718.37M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $970.23M 10-Q · filed 2026-05-07 | $807.84M derived: sum of 2 quarters · filed 2026-05-07 | $753.33M derived: sum of 3 quarters · filed 2026-05-07 | $713.11M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$162.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$216.90M derived: sum of 2 quarters · filed 2026-02-19 | -$257.12M derived: sum of 3 quarters · filed 2026-02-19 | -$302.57M 10-K · filed 2026-02-19 | ||||
| 2024-09-30 | -$54.51M 10-Q · filed 2025-11-04 | -$94.73M derived: sum of 2 quarters · filed 2025-11-04 | -$140.18M 10-Q · filed 2025-11-04 | -$134.36M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-06-30 | -$40.22M 10-Q · filed 2025-08-07 | -$85.67M 10-Q · filed 2025-08-07 | -$79.85M derived: sum of 3 quarters · filed 2026-02-19 | -$198.01M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-03-31 | -$45.45M 10-Q · filed 2025-05-06 | -$39.63M derived: sum of 2 quarters · filed 2026-02-19 | -$157.80M derived: sum of 3 quarters · filed 2026-02-19 | -$367.34M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2023-12-31 | $5.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$112.34M derived: sum of 2 quarters · filed 2026-02-19 | -$321.89M derived: sum of 3 quarters · filed 2026-02-19 | -$439.50M 10-K · filed 2026-02-19 | ||||
| 2023-09-30 | -$118.16M 10-Q · filed 2024-11-07 | -$327.71M derived: sum of 2 quarters · filed 2024-11-07 | -$445.32M 10-Q · filed 2024-11-07 | -$645.66M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | -$209.54M 10-Q · filed 2024-08-08 | -$327.16M 10-Q · filed 2024-08-08 | -$527.50M derived: sum of 3 quarters · filed 2025-02-27 | -$595.69M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | -$117.61M 10-Q · filed 2024-04-25 | -$317.96M derived: sum of 2 quarters · filed 2025-02-27 | -$386.14M derived: sum of 3 quarters · filed 2025-02-27 | -$478.50M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | -$200.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$268.53M derived: sum of 2 quarters · filed 2025-02-27 | -$360.89M derived: sum of 3 quarters · filed 2025-02-27 | -$447.41M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | -$68.19M 10-Q · filed 2023-10-26 | -$160.55M derived: sum of 2 quarters · filed 2023-10-26 | -$247.07M 10-Q · filed 2023-10-26 | -$331.80M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-06-30 | -$92.36M 10-Q · filed 2023-08-03 | -$178.88M 10-Q · filed 2023-08-03 | -$263.61M derived: sum of 3 quarters · filed 2024-02-29 | -$356.69M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-03-31 | -$86.52M 10-Q · filed 2023-04-27 | -$171.25M derived: sum of 2 quarters · filed 2024-02-29 | -$264.33M derived: sum of 3 quarters · filed 2024-02-29 | -$362.82M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | -$84.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$177.81M derived: sum of 2 quarters · filed 2024-02-29 | -$276.30M derived: sum of 3 quarters · filed 2024-02-29 | -$374.44M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | -$93.08M 10-Q · filed 2022-10-27 | -$191.57M derived: sum of 2 quarters · filed 2022-10-27 | -$289.71M 10-Q · filed 2022-10-27 | -$386.09M derived: sum of 4 quarters · filed 2022-10-27 | ||||
| 2021-06-30 | -$98.49M 10-Q · filed 2022-08-04 | -$196.64M 10-Q · filed 2022-08-04 | -$293.01M derived: sum of 3 quarters · filed 2022-08-04 | -$348.15M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | -$98.15M 10-Q · filed 2022-05-03 | -$194.52M derived: sum of 2 quarters · filed 2022-05-03 | -$249.65M derived: sum of 3 quarters · filed 2022-05-03 | -$436.93M derived: sum of 4 quarters · filed 2022-05-03 | ||||
| 2020-12-31 | -$96.37M 10-K · filed 2021-02-25 | -$151.50M derived: sum of 2 quarters · filed 2021-10-28 | -$338.78M derived: sum of 3 quarters · filed 2021-10-28 | -$431.77M 10-K · filed 2023-02-21 | ||||
| 2020-09-30 | -$55.13M 10-Q · filed 2021-10-28 | -$242.40M derived: sum of 2 quarters · filed 2021-10-28 | -$335.39M 10-Q · filed 2021-10-28 | -$408.18M derived: sum of 4 quarters · filed 2021-10-28 | ||||
| 2020-06-30 | -$187.27M 10-Q · filed 2021-07-29 | -$280.26M 10-Q · filed 2021-07-29 | -$353.05M derived: sum of 3 quarters · filed 2021-07-29 | -$413.52M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2020-03-31 | -$92.99M 10-Q · filed 2021-05-04 | -$165.78M derived: sum of 2 quarters · filed 2021-05-04 | -$226.25M derived: sum of 3 quarters · filed 2021-05-04 | -$265.01M derived: sum of 4 quarters · filed 2021-05-04 | ||||
| 2019-12-31 | -$72.78M 10-K · filed 2021-02-25 | -$133.26M derived: sum of 2 quarters · filed 2021-02-25 | -$172.02M derived: sum of 3 quarters · filed 2021-02-25 | -$241.16M 10-K · filed 2022-02-22 | ||||
| 2019-09-30 | -$60.48M 10-K · filed 2021-02-25 | -$99.23M derived: sum of 2 quarters · filed 2021-02-25 | -$168.37M 10-Q · filed 2020-10-29 | -$213.51M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | -$38.76M 10-K · filed 2021-02-25 | -$107.90M 10-Q · filed 2020-08-05 | -$153.04M derived: sum of 3 quarters · filed 2021-02-25 | -$201.27M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | -$69.14M 10-K · filed 2021-02-25 | -$114.28M derived: sum of 2 quarters · filed 2021-02-25 | -$162.51M derived: sum of 3 quarters · filed 2021-02-25 | -$168.08M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | -$45.14M 10-K · filed 2020-03-02 | -$93.37M derived: sum of 2 quarters · filed 2020-03-02 | -$98.94M derived: sum of 3 quarters · filed 2020-03-02 | -$115.69M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | -$48.23M 10-K · filed 2020-03-02 | -$53.80M derived: sum of 2 quarters · filed 2020-03-02 | -$70.55M 10-Q · filed 2019-10-30 | -$65.09M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | -$5.57M 10-K · filed 2020-03-02 | -$22.32M 10-Q · filed 2019-08-06 | -$16.86M derived: sum of 3 quarters · filed 2020-03-02 | -$47.76M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | -$16.74M 10-K · filed 2020-03-02 | -$11.29M derived: sum of 2 quarters · filed 2020-03-02 | -$42.18M derived: sum of 3 quarters · filed 2020-03-02 | -$54.68M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $5.45M 10-K · filed 2019-03-01 | -$25.44M derived: sum of 2 quarters · filed 2019-03-01 | -$37.94M derived: sum of 3 quarters · filed 2019-03-01 | -$64.29M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | -$30.89M 10-K · filed 2019-03-01 | -$43.39M derived: sum of 2 quarters · filed 2019-03-01 | -$69.74M 10-Q · filed 2018-11-05 | -$94.74M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | -$12.50M 10-K · filed 2019-03-01 | -$38.85M 10-Q · filed 2018-08-07 | -$63.84M derived: sum of 3 quarters · filed 2019-03-01 | -$95.91M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | -$26.36M 10-K · filed 2019-03-01 | -$51.35M derived: sum of 2 quarters · filed 2019-03-01 | -$83.41M derived: sum of 3 quarters · filed 2019-03-01 | -$119.97M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | -$24.99M 10-K · filed 2018-03-06 | -$57.06M derived: sum of 2 quarters · filed 2018-03-06 | -$93.62M derived: sum of 3 quarters · filed 2018-03-06 | -$132.06M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | -$32.06M 10-K · filed 2018-03-06 | -$68.62M derived: sum of 2 quarters · filed 2018-03-06 | -$107.07M 10-Q · filed 2017-11-02 | -$155.27M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-06-30 | -$36.56M 10-K · filed 2018-03-06 | -$75.00M 10-Q · filed 2017-08-09 | -$123.20M derived: sum of 3 quarters · filed 2018-03-06 | -$165.44M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-03-31 | -$38.44M 10-K · filed 2018-03-06 | -$86.64M derived: sum of 2 quarters · filed 2018-03-06 | -$128.88M derived: sum of 3 quarters · filed 2018-03-06 | -$167.50M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2015-12-31 | -$48.20M 10-K · filed 2017-03-16 | -$90.43M derived: sum of 2 quarters · filed 2017-03-16 | -$129.06M derived: sum of 3 quarters · filed 2017-03-16 | -$167.13M 10-K · filed 2018-03-06 | ||||
| 2015-09-30 | -$42.23M 10-K · filed 2017-03-16 | -$80.86M derived: sum of 2 quarters · filed 2017-03-16 | -$118.93M 10-Q · filed 2016-11-03 | -$151.16M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | -$38.63M 10-K · filed 2017-03-16 | -$76.70M 10-Q · filed 2016-08-04 | -$108.93M derived: sum of 3 quarters · filed 2017-03-16 | -$136.53M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | -$38.07M 10-K · filed 2017-03-16 | -$70.30M derived: sum of 2 quarters · filed 2017-03-16 | -$97.90M derived: sum of 3 quarters · filed 2017-03-16 | -$123.27M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2014-12-31 | -$32.23M 10-K · filed 2016-02-29 | -$59.83M derived: sum of 2 quarters · filed 2016-02-29 | -$85.20M derived: sum of 3 quarters · filed 2016-02-29 | -$99.41M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | -$27.60M 10-K · filed 2016-02-29 | -$52.97M derived: sum of 2 quarters · filed 2016-02-29 | -$67.18M 10-Q · filed 2015-11-09 | -$85.28M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | -$25.37M 10-K · filed 2016-02-29 | -$39.58M 10-Q · filed 2015-07-31 | -$57.67M derived: sum of 3 quarters · filed 2016-02-29 | -$61.95M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | -$14.21M 10-K · filed 2016-02-29 | -$32.30M derived: sum of 2 quarters · filed 2016-02-29 | -$36.58M derived: sum of 3 quarters · filed 2016-02-29 | -$51.03M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | -$18.09M 10-K · filed 2015-03-02 | -$18.09M 10-K · filed 2014-03-06 | -$22.37M derived: sum of 2 quarters · filed 2015-03-02 | -$36.82M derived: sum of 3 quarters · filed 2015-03-02 | -$45.40M 10-K · filed 2016-02-29 | -$45.40M 10-K · filed 2014-03-06 | ||
| 2013-09-30 | -$4.28M 10-K · filed 2015-03-02 | -$4.28M 10-Q · filed 2013-11-14 | -$18.73M derived: sum of 2 quarters · filed 2015-03-02 | -$27.30M 10-Q · filed 2014-11-06 | -$27.30M 10-Q · filed 2013-11-14 | -$33.34M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | -$14.45M 10-K · filed 2015-03-02 | -$14.45M 10-Q · filed 2013-08-13 | -$23.03M 10-Q · filed 2014-08-07 | -$23.03M 10-Q · filed 2013-08-13 | -$29.06M derived: sum of 3 quarters · filed 2015-03-02 | -$36.12M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | -$8.58M 10-K · filed 2015-03-02 | -$8.58M 10-K · filed 2014-03-06 | -$14.61M derived: sum of 2 quarters · filed 2015-03-02 | -$21.67M derived: sum of 3 quarters · filed 2015-03-02 | -$29.16M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2012-12-31 | -$6.03M 10-K · filed 2014-03-06 | -$13.09M derived: sum of 2 quarters · filed 2014-03-06 | -$20.59M derived: sum of 3 quarters · filed 2014-03-06 | -$26.81M 10-K · filed 2015-03-02 | -$26.81M 10-K · filed 2014-03-06 | |||
| 2012-09-30 | -$7.06M 10-K · filed 2014-03-06 | -$14.55M derived: sum of 2 quarters · filed 2014-03-06 | -$20.77M 10-Q · filed 2013-11-14 | |||||
| 2012-06-30 | -$7.50M 10-K · filed 2014-03-06 | -$13.72M 10-Q · filed 2013-08-13 | ||||||
| 2012-03-31 | -$6.22M 10-K · filed 2014-03-06 | |||||||
| 2011-12-31 | $30.58M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |